Plain-English translation of NCT04561557 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing —a type of engineered immune cell therapy—to treat people with autoimmune diseases of the nervous system that have stopped responding to conventional medicines. The therapy works by targeting and eliminating certain immune cells (plasma cells) that are incorrectly attacking the nervous system. If successful, this treatment could offer hope to people whose conditions have become resistant to standard therapies.
Many people with autoimmune diseases of the nervous system—like neuromyelitis optica, myasthenia gravis, and multiple sclerosis—suffer repeated attacks even after trying multiple standard immunosuppressive treatments. This trial exists to test whether this medication can help people whose diseases have become resistant to conventional care.
You likely qualify if…
You likely don't qualify if…
You would receive an infusion of the CT103A cell therapy at a starting dose, then be closely monitored for safety and how well the treatment works. The trial begins with a small group of patients to ensure safety before potentially increasing the dose in other participants. You would have multiple clinic visits for blood tests, physical examinations, and assessments of your neurological symptoms over several months to track how you respond.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China